SCHEMBL2695355

SCHEMBL2695355

CC(C)CN1CCC2(CC1)CCN(C(=O)c1ccc(CN(Cc3nccn3C)Cc3nccn3C)cc1)CC2

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 12/20 0.60
CYP3A4 P08684 8/20 0.60
ALDH1A1 P00352 1/20 0.60
MAPK1 P28482 1/20 0.54
CYP1A2 P05177 2/20 0.48
TSHR P16473 4/20 0.46
CYP2C9 P11712 3/20 0.46
USP2 O75604 3/20 0.46
HIF1A Q16665 2/20 0.46
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CCR8 P51685 1/20 0.42
KCNH2 Q12809 1/20 0.42
HRH3 Q9Y5N1 1/20 0.42
CXCR4 P61073 1/20 0.42
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2695556 0.95 CYP2D6 (0.53) CYP2D6CYP3A4ALDH1A1MAPK1CYP1A2
SCHEMBL2693871 0.92 CXCR4 (0.53) CYP2D6CYP3A4ALDH1A1MAPK1CYP1A2
SCHEMBL2692456 0.87 CXCR4 (0.55) CYP2D6CYP3A4ALDH1A1MAPK1CYP1A2
SCHEMBL2694565 0.85 CHRM2 (0.45) CYP2D6CYP3A4ALDH1A1MAPK1
SCHEMBL2692173 0.82 CYP3A4 (0.39) CYP2D6CYP3A4ALDH1A1CYP1A2TSHR
SCHEMBL2695977 0.81 CXCR4 (0.60) CYP2D6CYP3A4ALDH1A1MAPK1CYP1A2
SCHEMBL2695474 0.80 CXCR4 (0.61) CYP2D6CYP3A4ALDH1A1MAPK1CYP1A2
SCHEMBL2693583 0.80 HRH3 (0.41) CYP2D6CYP3A4ALDH1A1CYP1A2TSHR
SCHEMBL2696569 0.79 CXCR4 (0.56) CYP2D6CYP3A4ALDH1A1MAPK1CYP1A2
SCHEMBL2696738 0.79 CXCR4 (0.47) CYP2D6CYP3A4ALDH1A1CXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US claimed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP claimed
US-8519124-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2013-08-27 US disclosed
EP-1961744-B1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO (JP) 2013-04-17 EP disclosed
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2012-08-16 US disclosed
US-8168783-B2 Chemokine receptor antagonists and use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2012-05-01 US disclosed
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD., (JP) 2009-07-02 US disclosed
EP-1961744-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2008-08-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090169567-A1 BASIC GROUP-CONTAINING COMPOUND AND USE THEREOF CXCR4, CXCL12, CXCR3 CYP2D6 2687/4885CYP3A4 3747/4885ALDH1A1 470/4885
US-20120207765-A1 CHEMOKINE RECEPTOR ANTAGONISTS AND USE THEREOF CXCR4, CXCR3, CXCR1 CYP2D6 2851/4885CYP3A4 4052/4885ALDH1A1 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.